Ramasco Fernando, Méndez Rosa, Suarez de la Rica Alejandro, González de Castro Rafael, Maseda Emilio
Department of Anaesthesiology and Surgical Intensive Care, Hospital Universitario de La Princesa, Diego de León 62, 28006 Madrid, Spain.
Department of Anaesthesiology and Surgical Intensive Care, Hospital Universitario de León, 24071 León, Spain.
J Pers Med. 2024 Jan 18;14(1):106. doi: 10.3390/jpm14010106.
The main recent change observed in the field of critical patient infection has been universal awareness of the need to make better use of antimicrobials, especially for the most serious cases, beyond the application of simple and effective formulas or rigid protocols. The increase in resistant microorganisms, the quantitative increase in major surgeries and interventional procedures in the highest risk patients, and the appearance of a significant number of new antibiotics in recent years (some very specifically directed against certain mechanisms of resistance and others with a broader spectrum of applications) have led us to shift our questions from "what to deal with" to "how to treat". There has been controversy about how best to approach antibiotic treatment of complex cases of sepsis. The individualized and adjusted dosage, the moment of its administration, the objective, and the selection of the regimen are pointed out as factors of special relevance in a critically ill patient where the frequency of resistant microorganisms, especially among the Enterobacterales group, and the emergence of multiple and diverse antibiotic treatment alternatives have made the appropriate choice of antibiotic treatment more complex, requiring a constant updating of knowledge and the creation of multidisciplinary teams to confront new infections that are difficult to treat. In this article, we have reviewed the phenomenon of the emergence of resistance to antibacterials and we have tried to share some of the ideas, such as stewardship, sparing carbapenems, and organizational, microbiological, pharmacological, and knowledge tools, that we have considered most useful and effective for individualized decision making that takes into account the current context of multidrug resistance. The greatest challenge, therefore, of decision making in this context lies in determining an effective, optimal, and balanced empirical antibiotic treatment.
在危重症患者感染领域,近期观察到的主要变化是,人们普遍意识到需要更好地使用抗菌药物,尤其是针对最严重的病例,这超越了简单有效的方案或严格规程的应用。耐药微生物的增加、高危患者中大手术和介入性操作数量的增多,以及近年来大量新型抗生素的出现(有些非常专门针对某些耐药机制,另一些具有更广泛的应用谱),促使我们将问题从“应对什么”转变为“如何治疗”。关于如何最佳地处理复杂脓毒症病例的抗生素治疗存在争议。在危重症患者中,耐药微生物的出现频率,尤其是在肠杆菌科菌群中,以及多种不同抗生素治疗方案的出现,使得抗生素治疗的恰当选择变得更加复杂,这就需要不断更新知识并组建多学科团队来应对难以治疗的新感染,此时,个体化和调整剂量、给药时机、目标以及治疗方案的选择被指出是特别相关的因素。在本文中,我们回顾了抗菌药物耐药性出现的现象,并试图分享一些我们认为对于考虑到当前多重耐药背景下的个体化决策最有用和有效的想法,例如管理、碳青霉烯类药物的节约使用以及组织、微生物学、药理学和知识工具等。因此,在这种情况下决策面临的最大挑战在于确定一种有效、最佳且平衡的经验性抗生素治疗方案。